First-Line Management of MAFLD (MASLD)
Lifestyle modification through dietary changes and weight loss is the cornerstone first-line treatment for all adults with MAFLD, with a target of sustained weight reduction of >5% to reduce liver fat, 7-10% to improve inflammation, and >10% to improve fibrosis 1.
Core Treatment Algorithm
1. Weight Loss Through Dietary Intervention (Strong Recommendation)
The evidence is unequivocal that dietary and behavioral therapy-induced weight loss improves liver injury both histologically and non-invasively 1. The magnitude of weight loss directly correlates with therapeutic benefit:
- >5% weight loss: Reduces hepatic steatosis
- 7-10% weight loss: Improves liver inflammation
- >10% weight loss: Improves fibrosis 1
Dietary Pattern: Adopt a Mediterranean dietary pattern, which has the strongest evidence base 1, 2. This means:
- Emphasizing plant-based foods, whole grains, legumes, nuts, olive oil
- Limiting ultra-processed foods rich in sugars and saturated fats
- Completely avoiding sugar-sweetened beverages 1
2. Physical Activity and Exercise (Strong Recommendation)
Physical activity reduces steatosis independent of weight loss 1. The specific targets are:
- ≥150 minutes/week of moderate-intensity activity, OR
- ≥75 minutes/week of vigorous-intensity activity
- Both aerobic and resistance training are effective 2
Tailor the exercise regimen to individual preference and ability to maximize adherence 1.
3. Alcohol Abstinence
Discourage all alcohol consumption 3. For patients with significant fibrosis (stage ≥2), complete alcohol abstinence is mandatory 4.
4. Optimize Cardiometabolic Comorbidities (Critical Component)
A multidisciplinary approach targeting all cardiometabolic components is essential 1. This includes:
- Type 2 diabetes management: Consider incretin-based therapies (semaglutide, tirzepatide) if indicated 3
- Obesity management: Use GLP-1 receptor agonists when appropriate
- Hypertension control
- Dyslipidemia management
The rationale: MASLD is bidirectionally connected to cardiometabolic disease, and cardiovascular disease is the leading cause of death in these patients—not liver disease 5. Therefore, addressing metabolic risk factors improves both liver-related and extrahepatic outcomes 1.
Important Caveats and Pitfalls
Common Pitfall #1: Focusing solely on liver outcomes while neglecting cardiovascular risk. Remember that cardiovascular disease, not liver failure, is the primary cause of mortality in MAFLD patients 5.
Common Pitfall #2: Underestimating the difficulty of lifestyle adherence. The 2024 EASL-EASD-EASO guidelines acknowledge that uptake of lifestyle interventions is challenging 2. Success requires behavioral support, personalization of recommendations, and sustainability planning 2.
Common Pitfall #3: Not staging fibrosis before treatment. Use FIB-4 score initially, followed by transient elastography if needed, to identify patients with advanced fibrosis who may benefit from pharmacotherapy 3.
When to Consider Advanced Interventions
Bariatric Surgery
Consider bariatric surgery for patients with MAFLD and obesity (BMI >35) who fail lifestyle and medical interventions 3, 4.
Pharmacotherapy
For patients with non-cirrhotic MASH and significant fibrosis (stage ≥2), consider:
- Resmetirom (if locally approved): First FDA-approved MASH-targeted therapy with demonstrated histological effectiveness 3
- Semaglutide: Conditionally FDA-approved for MASH with moderate to advanced fibrosis 5
- Pioglitazone or SGLT-2 inhibitors: Based on presence of diabetes and individual risk factors 4
Critical Note: No MASH-targeted pharmacotherapy is currently recommended for cirrhotic stage disease 3.
Monitoring and Follow-up
Use non-invasive tests (FIB-4, transient elastography) for repeated assessment of fibrosis progression, though these provide limited information about treatment response at the individual level 1. Liver biopsy is not suited for routine monitoring due to invasiveness 1.
For cirrhotic patients: Implement surveillance for portal hypertension and hepatocellular carcinoma, with consideration for liver transplantation in decompensated cirrhosis 3.